Athenex forges new deals in China and wins $100 million investment

3 July 2018
mergers-acquisitions-big

East Coast, USA-based firm Athenex (Nasdaq:ATNX), has announced several key strategic deals focused on China, aimed at furthering its oncology developments.

First, the firm says it has agreed a new joint venture (JV) with a subsidiary of Guangzhou Xiangxue Pharmaceutical to develop and commercialize T-cell receptor-engineered T cells (TCR-T), a cancer immunotherapy technology, based on a novel approach.

At the same time, Athenex has made a strategic expansion into biologics for oncology, gaining worldwide rights to a pegylated genetically modified human arginase from a subsidiary of Hong Kong-based Avalon Biomedical Management.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology